Pharma Tech

Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat

Aug 12, 2026, 9:14 AM

Translate article text

Choose a language and wait for the translated text.

Mereo BioPharma and Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for AATD-LD.